Bliss GVS Pharma Expands Share Capital Through Employee Stock Option Allotment

Bliss GVS Pharma Limited , a prominent player in the pharmaceutical sector, has recently expanded its share capital through the allotment of equity shares under its Employee Stock Option Plan (ESOP). This move underscores the company's commitment to employee incentivization and aligns with its growth strategy.

Key Details of the Allotment

The ESOP Allotment Committee of Bliss GVS Pharma approved the issuance of 33,670 equity shares on November 5, 2025. These shares, each with a face value of Re. 1, were allotted to eligible employees who exercised their stock options under the company's Employee Stock Option Plan 2019 (Bliss GVS ESOP-2019).

Impact on Share Capital

Following this allotment, the company's share capital structure has undergone the following changes:

Aspect	Before Allotment	After Allotment
Total Issued Shares	10,56,88,923	10,57,22,592
Issued Share Capital	Rs. 10,56,88,923	Rs. 10,57,22,592

Financial and Regulatory Aspects

Exercise Price: The shares were allotted at an exercise price of Rs. 43.00 per share, which includes a premium of Rs. 42.00 per share.
Lock-in Period: The newly allotted shares are subject to a lock-in period of six months from the date of allotment, set to expire on May 5, 2026.
Listing: The shares are expected to be listed on both the BSE Limited and the National Stock Exchange of India Limited, where the company's existing shares are traded.
ISIN: The allotted shares carry the ISIN INE416D01022, consistent with the company's existing equity shares.

Regulatory Compliance

This allotment is in compliance with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The company has duly informed the stock exchanges about this corporate action, adhering to the principles of transparency and regulatory disclosure.

Implications for Investors and Employees

For existing shareholders, this allotment represents a marginal dilution of 0.03% in their shareholding. However, it also signifies the company's focus on aligning employee interests with those of the shareholders, potentially driving long-term value creation.

For the employees who received these shares, it presents an opportunity to participate in the company's equity and benefit from its future growth, subject to the specified lock-in period.

As Bliss GVS Pharma continues to navigate the dynamic pharmaceutical landscape, this ESOP allotment serves as a testament to its strategy of fostering employee engagement and retention through equity participation.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.96%	+1.14%	+0.12%	+31.19%	+23.95%	-8.09%

Bliss GVS Pharma Limited , a prominent player in the pharmaceutical sector, has announced robust financial results for the first quarter of fiscal year 2026, alongside a significant employee stock option grant.

Strong Financial Performance

The company delivered impressive quarterly results for Q1 FY2026, with consolidated net profit more than doubling to ₹430.00 million, up from ₹207.00 million in the same period last year. This remarkable growth was accompanied by a solid increase in revenue, which rose to ₹2,070.00 million from ₹1,840.00 million year-over-year.

Bliss GVS Pharma also reported a substantial improvement in its EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization), which increased to ₹413.00 million from ₹343.00 million in the corresponding quarter of the previous year. The EBITDA margin saw a notable enhancement, rising to 19.92% from 18.69%.

Financial Metric	Q1 FY2026 (₹ in million)	Q1 FY2025 (₹ in million)	YoY Growth
Net Profit	430.00	207.00	107.73%
Revenue	2,070.00	1,840.00	12.50%
EBITDA	413.00	343.00	20.41%
EBITDA Margin	19.92%	18.69%	1.23pp

Board Approval and Regulatory Compliance

The Board of Directors of Bliss GVS Pharma convened on July 29, 2025, to approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2025. The meeting, which began at 1:00 p.m. and concluded at 4:30 p.m., was held at the company's registered office.

In compliance with regulatory requirements, the company has submitted copies of the unaudited financial results along with the Limited Review Report of the Auditors to both the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE).

Employee Stock Option Plan

In a move aimed at aligning employee interests with company performance, the Nomination and Remuneration Committee of Bliss GVS Pharma has approved the grant of 268,000 stock options under the company's Employee Stock Options Plan 2019. This decision was made during a committee meeting held on July 29, 2025.

Key details of the stock option grant include:

Each option is convertible into one equity share with a face value of ₹1.00.
The exercise price is set at ₹43.00 per option/share, based on the NSE last closing market price on July 28, 2025, with a 72.28% discount applied.
The options will vest over four years, with 25% vesting each year, starting 12 months from the grant date.
Vested options can be exercised within six months of vesting.
Shares acquired through this plan will be subject to a six-month lock-in period from the date of allotment.

This strategic move is expected to enhance employee motivation and retention while aligning their interests with the company's long-term growth objectives.

Bliss GVS Pharma's strong financial performance and proactive employee incentive measures reflect the company's robust business strategy and commitment to stakeholder value. As the pharmaceutical sector continues to evolve, Bliss GVS Pharma appears well-positioned for sustained growth and innovation.